In conclusion, our results show that bortezomib-mediated inhibition of cell proliferation of CML cell lines is associated with down-regulation of SKP2 with concomitant up-regulation/stabilization of p27Kip1. Here, SKP2 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.